JP5486744B2 - ムユヨの花、トゲバンレイシの葉、及びウコンの根の抽出物を含む、肝炎を治療するための組成物 - Google Patents
ムユヨの花、トゲバンレイシの葉、及びウコンの根の抽出物を含む、肝炎を治療するための組成物 Download PDFInfo
- Publication number
- JP5486744B2 JP5486744B2 JP2010527309A JP2010527309A JP5486744B2 JP 5486744 B2 JP5486744 B2 JP 5486744B2 JP 2010527309 A JP2010527309 A JP 2010527309A JP 2010527309 A JP2010527309 A JP 2010527309A JP 5486744 B2 JP5486744 B2 JP 5486744B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- extract
- herbal composition
- liver
- turmeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 120
- 239000000284 extract Substances 0.000 title claims description 61
- 235000003373 curcuma longa Nutrition 0.000 title claims description 31
- 208000006454 hepatitis Diseases 0.000 title description 4
- 231100000283 hepatitis Toxicity 0.000 title description 2
- 238000011282 treatment Methods 0.000 claims description 73
- 244000163122 Curcuma domestica Species 0.000 claims description 25
- 208000019423 liver disease Diseases 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 16
- 235000013976 turmeric Nutrition 0.000 claims description 16
- 206010067125 Liver injury Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 230000002443 hepatoprotective effect Effects 0.000 claims description 12
- 208000036142 Viral infection Diseases 0.000 claims description 9
- 231100000234 hepatic damage Toxicity 0.000 claims description 9
- 230000008818 liver damage Effects 0.000 claims description 9
- 230000009385 viral infection Effects 0.000 claims description 9
- 240000004749 Annona muricata Species 0.000 claims description 7
- 235000007747 Annona muricata Nutrition 0.000 claims description 7
- 241001325266 Cordia Species 0.000 claims description 7
- 241000244741 Cordia lutea Species 0.000 claims description 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 6
- 240000008397 Ganoderma lucidum Species 0.000 claims description 5
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 5
- 230000007882 cirrhosis Effects 0.000 claims description 5
- 231100000753 hepatic injury Toxicity 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 241000722951 Annona Species 0.000 claims description 4
- 235000007755 Annona Nutrition 0.000 claims description 4
- 235000011518 Annona purpurea Nutrition 0.000 claims description 4
- 235000014375 Curcuma Nutrition 0.000 claims description 4
- 206010019799 Hepatitis viral Diseases 0.000 claims description 3
- 201000001862 viral hepatitis Diseases 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 239000001215 curcuma longa l. root Substances 0.000 claims 1
- 239000008513 turmeric extract Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 45
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 36
- 210000003494 hepatocyte Anatomy 0.000 description 28
- 238000012360 testing method Methods 0.000 description 28
- 241000700159 Rattus Species 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 26
- 238000000034 method Methods 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 241000196324 Embryophyta Species 0.000 description 22
- 230000003859 lipid peroxidation Effects 0.000 description 20
- 210000004185 liver Anatomy 0.000 description 19
- 229960003180 glutathione Drugs 0.000 description 18
- 230000003078 antioxidant effect Effects 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 16
- 208000005176 Hepatitis C Diseases 0.000 description 14
- 238000005259 measurement Methods 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- 230000007423 decrease Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 12
- 239000003963 antioxidant agent Substances 0.000 description 11
- 235000006708 antioxidants Nutrition 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 108010050904 Interferons Proteins 0.000 description 10
- 102000014150 Interferons Human genes 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 229940079322 interferon Drugs 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 9
- 208000010710 hepatitis C virus infection Diseases 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 238000006722 reduction reaction Methods 0.000 description 9
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 8
- 108010024636 Glutathione Proteins 0.000 description 8
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 231100000252 nontoxic Toxicity 0.000 description 8
- 230000003000 nontoxic effect Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- 238000002604 ultrasonography Methods 0.000 description 8
- 208000006154 Chronic hepatitis C Diseases 0.000 description 7
- 206010016654 Fibrosis Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 208000002672 hepatitis B Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000004998 Abdominal Pain Diseases 0.000 description 5
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 5
- 206010028813 Nausea Diseases 0.000 description 5
- 230000007059 acute toxicity Effects 0.000 description 5
- 231100000403 acute toxicity Toxicity 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 230000008693 nausea Effects 0.000 description 5
- 235000017807 phytochemicals Nutrition 0.000 description 5
- 229930000223 plant secondary metabolite Natural products 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 5
- 229960000329 ribavirin Drugs 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 229920001864 tannin Polymers 0.000 description 5
- 235000018553 tannin Nutrition 0.000 description 5
- 239000001648 tannin Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 150000003648 triterpenes Chemical class 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010019851 Hepatotoxicity Diseases 0.000 description 4
- 208000000112 Myalgia Diseases 0.000 description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 244000290333 Vanilla fragrans Species 0.000 description 4
- 235000009499 Vanilla fragrans Nutrition 0.000 description 4
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000006286 aqueous extract Substances 0.000 description 4
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 4
- 238000012742 biochemical analysis Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 231100000304 hepatotoxicity Toxicity 0.000 description 4
- 230000007686 hepatotoxicity Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 208000013465 muscle pain Diseases 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 235000005875 quercetin Nutrition 0.000 description 4
- 229960001285 quercetin Drugs 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 208000019116 sleep disease Diseases 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000001263 FEMA 3042 Substances 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000012675 alcoholic extract Substances 0.000 description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 235000001671 coumarin Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 3
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 229940054441 o-phthalaldehyde Drugs 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- -1 oxygen radical species Chemical class 0.000 description 3
- 238000002559 palpation Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 208000022925 sleep disturbance Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000015523 tannic acid Nutrition 0.000 description 3
- 229940033123 tannic acid Drugs 0.000 description 3
- 229920002258 tannic acid Polymers 0.000 description 3
- 150000003505 terpenes Chemical class 0.000 description 3
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- HWHNFJYQDMSYAF-UHFFFAOYSA-O 1,5-dimethyl-2h-tetrazol-1-ium Chemical compound C[NH+]1N=NN=C1C HWHNFJYQDMSYAF-UHFFFAOYSA-O 0.000 description 2
- HDHQZCHIXUUSMK-UHFFFAOYSA-N 4-hydroxy-2-quinolone Chemical class C1=CC=C2C(O)=CC(=O)NC2=C1 HDHQZCHIXUUSMK-UHFFFAOYSA-N 0.000 description 2
- VXIXUWQIVKSKSA-UHFFFAOYSA-N 4-hydroxycoumarin Chemical compound C1=CC=CC2=C1OC(=O)C=C2O VXIXUWQIVKSKSA-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 238000008789 Direct Bilirubin Methods 0.000 description 2
- 206010013082 Discomfort Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 108010063907 Glutathione Reductase Proteins 0.000 description 2
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 description 2
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000006268 Sarcoma 180 Diseases 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- WBROFWPLLSCFBK-HWXHKDKUSA-N [(1r,3ar,5ar,5br,7ar,9s,11ar,11br,13br)-3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound C([C@@]1(C)CC[C@H]([C@@H]1C1CC[C@H]23)C(C)=C)C[C@@]1(C)[C@]3(C)CC[C@@H]1[C@]2(C)CC[C@H](OC(=O)CCCCCCC/C=C/C/C=C/CCCCC)C1(C)C WBROFWPLLSCFBK-HWXHKDKUSA-N 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 208000024330 bloating Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 150000004775 coumarins Chemical class 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000036267 drug metabolism Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 201000010235 heart cancer Diseases 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000024348 heart neoplasm Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000002035 hexane extract Substances 0.000 description 2
- 239000000399 hydroalcoholic extract Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 231100000580 in vitro toxicity testing Toxicity 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000002311 liver mitochondria Anatomy 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000051 modifying effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 231100000620 pharmacotoxicology Toxicity 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 238000009160 phytotherapy Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229930000044 secondary metabolite Natural products 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- BENRIKOGQFXSRY-UHFFFAOYSA-N (8-acetyloxy-4-methyl-2-oxochromen-7-yl) acetate Chemical compound CC1=CC(=O)OC2=C(OC(C)=O)C(OC(=O)C)=CC=C21 BENRIKOGQFXSRY-UHFFFAOYSA-N 0.000 description 1
- KQJSQWZMSAGSHN-UHFFFAOYSA-N (9beta,13alpha,14beta,20alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(O)=C2C KQJSQWZMSAGSHN-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N 3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-3,4-dihydro-2H-1-benzopyran-4-one Chemical compound C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- MLCMXDYMSAZNPC-UHFFFAOYSA-N 4-methoxychromen-2-one Chemical compound C1=CC=CC2=C1OC(=O)C=C2OC MLCMXDYMSAZNPC-UHFFFAOYSA-N 0.000 description 1
- PSGQCCSGKGJLRL-UHFFFAOYSA-N 4-methyl-2h-chromen-2-one Chemical class C1=CC=CC2=C1OC(=O)C=C2C PSGQCCSGKGJLRL-UHFFFAOYSA-N 0.000 description 1
- NWQBYMPNIJXFNQ-UHFFFAOYSA-N 7,8-dihydroxy-4-methyl-1-benzopyran-2-one Chemical compound OC1=C(O)C=CC2=C1OC(=O)C=C2C NWQBYMPNIJXFNQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001072256 Boraginaceae Species 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- AQKDBFWJOPNOKZ-UHFFFAOYSA-N Celastrol Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(=O)C2C AQKDBFWJOPNOKZ-UHFFFAOYSA-N 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 235000019015 Cordia abyssinica Nutrition 0.000 description 1
- 244000157795 Cordia myxa Species 0.000 description 1
- 235000004257 Cordia myxa Nutrition 0.000 description 1
- 241000326241 Cordia verbenacea Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 231100000750 In vitro toxicology Toxicity 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010014865 PLIalpha Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940123898 Phospholipase A2 inhibitor Drugs 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 108010012770 Rebetron Proteins 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- 241001466077 Salina Species 0.000 description 1
- 244000209710 Samanea saman Species 0.000 description 1
- KEOITPILCOILGM-FCWYPSSHSA-N Sapindoside A Natural products O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O7)[C@H](O)[C@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2 KEOITPILCOILGM-FCWYPSSHSA-N 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241001326030 Tournefortia Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 235000007212 Verbena X moechina Moldenke Nutrition 0.000 description 1
- 240000001519 Verbena officinalis Species 0.000 description 1
- 235000001594 Verbena polystachya Kunth Nutrition 0.000 description 1
- 235000007200 Verbena x perriana Moldenke Nutrition 0.000 description 1
- 235000002270 Verbena x stuprosa Moldenke Nutrition 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- KBYYTUYPCGPQNK-UHFFFAOYSA-N alpha-hederin Natural products CC1OC(OC2C(O)C(CO)OC2OC3CCC4(C)C(CCC5(C)C4CC=C6C7CC(C)(C)CCC7(CCC56C)C(=O)O)C3(C)CO)C(O)C(O)C1O KBYYTUYPCGPQNK-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008503 anti depressant like effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 201000007637 bowel dysfunction Diseases 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000731 choleretic agent Substances 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229920001968 ellagitannin Polymers 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 230000002178 gastroprotective effect Effects 0.000 description 1
- 231100000420 gastrotoxicity Toxicity 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000011194 good manufacturing practice Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 235000012171 hot beverage Nutrition 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- KEOITPILCOILGM-LLJOFIFVSA-N kalopanaxsaponin A Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(CC[C@]6(CCC(C)(C)C[C@H]6C5=CC4)C(O)=O)C)(C)CC3)(C)CC2)(C)CO)OC[C@H](O)[C@@H]1O KEOITPILCOILGM-LLJOFIFVSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000014987 limb edema Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001706 oxygenating effect Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000003358 phospholipase A2 inhibitor Substances 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000004537 potential cytotoxicity Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000004800 psychological effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- QGVNJRROSLYGKF-UHFFFAOYSA-N thiobarbital Chemical compound CCC1(CC)C(=O)NC(=S)NC1=O QGVNJRROSLYGKF-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- BYKYTXUAKJDVPV-UHFFFAOYSA-N tritriacontane-16,18-dione Chemical compound CCCCCCCCCCCCCCCC(=O)CC(=O)CCCCCCCCCCCCCCC BYKYTXUAKJDVPV-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
クマリンは、植物界に豊富に見出すことができる別の種類のポリフェノール化合物である。それらの多くは、例えば4−メトキシクマリンは利胆特性を有しているなどの、興味深い生物学的活性を有している(Takeda,S.;Aburada,M.J.Pharmacobio−Dyn.4:724(1981))。7,8ジヒドロキシ−4−メチルクマリン及び7,8−ジアセトキシ−4−メチルクマリンは、抗酸化特性を有しており、従って酸素ラジカルの有効なスカベンジャーと考えられる(Raj,H.G.;Parmar,V.S.;Jain,S.C.;Priyadarsini,K.I.;Mittal,J.P.;Goel,S.;Poonam;Himanshu;Malhotra,S.;Singh,A.;Olsen,C.E.;Wngel,J.Bioorg.Med.Chem.6:833(1998))。加えて、この群の分子は、HepG2細胞及び初代ヒト肝細胞培養において既知酸化剤(t−ブチルヒドロペルオキシド)によって誘導された毒性に対して保護的効果を示す(Bernard Refouvelet,Catherine Guyon,Yves Jacquot,Corinne Girard,Herve Fein,Francoise Bevalotb,Jean−Francois Robert a,Bruno Heyd,Georges Mantion,Lysiane Richert,Alain Xicluna,Synthesis of 4−hydroxycounmarin and 2,4−quinolinediol derivatives and evaluation of their effects on the viability of HepG2 cells and human hepatocytes culture.European Journal of Medicinal Chemistry 39:931−937(2004))。
テルペノイドは、抗酸化作用(Zhu M,Chang Q,Wong LK,Chong FS,Li RC.Triterpene antioxidants from Ganoderma lucidum.Phytotherapy Research 13:529−31(1999))、及び肝保護作用(James,L.P.,Mayeux,P.R.,Honson,J.A.Acetaminophen−induced hepatotoxicity.Drug Metabolism Disposition 31:499−506(2003))も示す別の群の植物由来の代謝物である。トリテルペンセラストロールは、肝臓ミトコンドリアにおける脂質過酸化に対して強力な阻害効果を示す。In vitro及びin vivo実験において、他の臨床テストと同様に、オレイン酸、ウルソール酸、アルファ−ヘデリン、グリチルリジン及びルペオールなどのいくつかのテルペノイドは、胃保護の効果(Zhu M,Chang Q,Wong LK,Chong FS,Li RC.Triterpene antioxidants from Ganoderma lucidum.Phytotherapy Research 13:529−31(1999))、及び肝保護作用(Liu,J.,Liu,Y.,Mao,Q.The effects of 10 triterpenoid compounds on experimental liver injury in mice.Fundamental and Applied Toxicology 22:34−40(1994))(Sunitha S.,Nagaraj M.,Varalakshmi P.Hepatoprotective effect of lupeol and lupeol linoleate on tissue antioxidant defence system in cadmium−induced hepatotoxicity in rats.Fitoterapia 72:516−523(2001))を示した。
現在の治療法のいくつかの不都合に立ち向かうウイルス性及び非ウイルス性肝障害に対
する安全で有効な治療の必要性がある。
【先行技術文献】
【特許文献】
【特許文献1】 米国特許第5401777号
【特許文献2】 米国特許第5861415号
【特許文献3】 米国特許第6426098号
【特許文献4】 米国特許第6841177号
【特許文献5】 欧州公開第1032408号
【特許文献6】 国際公開第WO03051380号
【特許文献7】 国際公開第WO04048358号
【非特許文献】
【非特許文献1】 AFZAL, M., et al. Antioxidant Activity of Cordia Myxxa L. and its Hepatoprotective Potential. 2007. Electronic Journal of Environmental, Agricultural and Food Chemistry. Vol.6(6), pp. 2109−18.
【非特許文献2】 AL−AWADI, F.M., et al. Antiinflammatory Effects of Cordia myxa Fruit on Experimentally Induced Colitis in Rats. 2001. Nutrition. Vol. 17, pp. 391−6.
【非特許文献3】 BASKAR, R., et al. In vitro Antioxidant Studies in Leaves of Annona Species. 2007. Indian J Exp Biol. Vol 45(5), pp. 480−5.
【非特許文献4】 BAYEUX, M., et al. Evaluation of the Antiedematogenic Activity of Artemetin Isolated From Cordia curassavica DC. 2002. Brazilian Journal of Medical and Biological Research. Vol. 35, pp. 1229−32.
【非特許文献5】 BERRY, M.N. and FRIEND, D.S. High Yield Preparation of Isolated Rat Liver Parenchymal Cells. 1969. J Cell Biol. Vol. 43, pp. 506−20.
【非特許文献6】 BOOTS, A.W., et al. No Role of DT−Diaphorase (NqO1) in the Protection Against Oxidized Quercetin. 2005. FEBS Lett. Vol. 579, pp. 677−82.
【非特許文献7】 BUSSMANN R.W., et al. Traditional Medicinal Plant Use in Northern Peru: Tracking Two Thousand Years of Healing Culture. 2006. J Ethnobiol Ethnomed. Vol 2, p. 47. www.ethnobiomed.com/content/2/1/47.
【非特許文献8】 CHHABRA, S.C., et al. Phytochemical Screening of Tanzanian Medical Plants. 1984. J Ethnopharmacol. Vol. 11(2), pp. 157−79.
【非特許文献9】 DAVIS, G.L. Combination Therapy with Interferon Alpha and Ribavirin as Treatment of Interferon Relapse in Chronic Hepatitis C. 1999. Semin Liver Dis. Vol. 19(Suppl 1), pp. 49−55.
【非特許文献10】 DE SOUZA, G., et al. Ethnopharmacological Studies of Antimicrobial Remedies in the South of Brazil. 2004. Journal of Ethnopharmacology. Vol. 90, pp. 135−43.
【非特許文献11】 DESHPANDE, U.R., et al. Protective Effect of Tumeric (Curcuma longa L.) Extract on Carbon Tetrachloride−Induced Liver Damage in Rats. 1998. Indian J Exp Biol. Vol. 36(6), pp. 573−7.
【非特許文献12】 FICARRA, R., et al. Leaf Extracts of Some Cordia Species: Analgesic and Anti−Inflammatory Activities as Well as Their Chromatographic Analysis. 1995. Il Farmaco. Vol. 50(4), pp. 245−56.
【非特許文献13】 HERNANDEZ, T., et al. Ethnobotany and Antibacterial Activity of Some Plants Used in Traditional Medicine of Zapotitlan de las Salinas, Puebla (Mexico). 2003. Journal of Ethnopharmacology. Vol. 88, pp. 181−8.
【非特許文献14】 HERNANDEZ, T., et al. Antimicrobial Activity of the Essential Oil and Extracts of Cordia curassavica (Boraginaceae). 2007. Jounal of Ethnopharmacology. Vol. 111, pp. 137−41.
【非特許文献15】 HIROSE, M., et al. Modifying Effects of the Naturally Occurring Antioxidants Gamma−oryzanol, Phytic Acid, Tannic Acid and n−Tritriacontane−16,18−dione in a Rat Wide−Spectrum Organ Carcinogenesis Model. 1991. Carcinogenesis. Vol. 12, pp. 1917−21.
【非特許文献16】 JAMES, L.P., et al. Acetaminophen−Induced Hepatotoxicity. 2003. Drug Metabolism Disposition. Vol. 31, pp. 499−506.
【非特許文献17】 KLOUCEK, P. Antimicrobial Activity of Some Medicinal Barks Used in Peruvian Amazon. 2007. Journal of Ethnopharmacology. Vol. 111, pp. 427−9.
【非特許文献18】 KUNCHANDY, E., and RAO, M.N.A. Effect of curcumin on hydroxyl radical generation through Fenton reaction. 1989. Int J Pharm. Vol. 57, pp. 173−6.
【非特許文献19】 LANS, C. Ethnomedicines Used in Trinidad and Tobago for Reproductive Problems. 2007. Journal of Ethnobiology and Ethnomedicine. Vol. 3(13), pp. 1−12.
【非特許文献20】 LAUTRAITE, S., et al. Optimisation of Cell−Based Assays for Medium Throughput Screening of Oxidative Stress. 2003. Toxicol in vitro. Vol. 17, pp. 207−220.
【非特許文献21】 LIN, Y.L., et al. Anti−lipid−peroxidative Principles from Tounefortia samentosa. 2002. J Nat Prod. Vol. 65(5), pp. 745−7.
【非特許文献22】 LIU, J., et al. The Effects of 10 Triterpenoid Compounds on Experimental Liver Injury in Mice. 1994. Fundamental and Applied Toxicology. Vol. 22, pp. 34−40.
【非特許文献23】 LUPER, S. A Review of Plants Used in the Treatment of Liver Disease: Part Two. 1999. Alternative Medicine Review. Vol. 4(3), pp. 178−88.
【非特許文献24】 MCHUTCHISON, J.G., and POYNARD, T. Combination Therapy with Interferon Plus Ribavirin for the Initial Treatment of Chronic Hepatitis C. 1999. Semin Liver Dis. Vol. 19(Suppl 1), pp. 57−65..
【非特許文献25】 MEDEIROS, R., et al. Effect of Two Active Compounds Obtained from the Essential Oil of Cordia verbenacea on the Acute Inflammatory Responses Elicited by LPS in the Rat Paw. 2007. British Journal of Pharmacology. Pp. 1−10.
【非特許文献26】 MIDDLETON Jr., E., et al. The Effects of Plant Flavonoids on Mammalian Cells: Implications for Inflammation, Heart Disease, and Cancer. 2000. Pharmacol Rev. Vol. 52, pp. 673−751.
【非特許文献27】 MIYAMOTO, K.I., et al. Antitumor Activities of Ellagitannins Against Sarcoma−180 in Mice. 1993. Biol Pharm Bull. Vol. 16, pp. 379−87.
【非特許文献28】 MOLINA−SALINAS, G., et al. Evaluation of the Flora of Northern Mexico for in vitro Antimicrobial and Antituberculosis Activity. 2007. Journal of Ethnopharmacology. Vol. 109, pp. 435−41.
【非特許文献29】 MORA S., et al. Anxiolytic and Antidepressant−like Effects of the Hydroalcohol Extract from Aloysia polystachya in Rats. 2005. Pharmacol Biochem Behav. Vol. 82(2), pp. 373−8.
【非特許文献30】 OKUDA, T., et al. Studies on the Activities of Tannins and Related Compounds from Medicinal Plants and Drugs. I. Inhibitory Effects on Lipid Peroxidation in Mitochondria and Microsomes of Liver. 1983. Chem Pharm Bull. Vol. 31, pp. 1625−31.
【非特許文献31】 PASSOS, G., et al. Anti−Inflammatory and Anti−Allergic Properties of the Essential Oil and Active Compounds from Cordia verbenacea. 2007. Journal of Ethnopharmacology. Vol. 110, pp. 323−33.
【非特許文献32】 Raintree Nutrition Monograph. 2004. pp. 1−10. www.rain−tree.com/Graviola−Monograph.pdf
【非特許文献33】 RAJ, H.G., et al. Mechanism of Biochemical Action of Substituted 4−Methylbenzopyran−2−ones. Part I: Dioxygenated 4−methyl Coumarins as Superb Antioxidant and Radical Scavenging Agents. 1998. J Bioorg Med Chem. Vol. 6, p. 833.
【非特許文献34】 REDDY, A.C., and LOKESH, B.R. Effect of Dietary Tumeric (Curcuma longa) on Iron−induced Lipid Peroxidation in the Rat Liver. 1994. Food Chem Toxicol. Vol. 32, pp. 279−283.
【非特許文献35】 REFOUVELET, B., et al. Synthesis of 4−Hydroxycoumarin and 2,4−quinolinediol Derivatives and Evaluation of Their Effects on the Viability of HepG2 Cells and Human Hepatocytes Culture. 2004. European Journal of Medicinal Chemistry. Vol. 39, pp. 931−7.
【非特許文献36】 RUI, Y.C. Advances in Pharmacological Studies of Silymarin. 1991. Mem Inst Oswaldo Cruz.Vol. 86, pp. 79−85.
【非特許文献37】 SATOH, K., and SAKAGAMI, H. Ascorbyl Radical Scavenging Activity of Polyphenols. 1996. Anticancer Res. Vol. 16, pp. 2885−90.
【非特許文献38】 SCEVOLA, D., et al. Flavonoids and Hepatic Cyclic Monophosphates in Liver Injury. 1984. Boll Ins Sieroter Milan. Vol. 63, pp. 77−82.
【非特許文献39】 SERTIE, J., et al. Pharmacological Assay of Cordia verbenacea III: Oral and Topical Antiinflammatory Activity and Gastrotoxicity of a Crude Leaf Extract. 1991. Journal of Ethnopharmacology. Vol. 31, pp. 239−47.
【非特許文献40】 SIDDIQUI, B., et al. Studies on the Chemical Constituents of the fruits of Cordia latifolia. 2006. Natural Product Research. Vol. 20(2), pp. 131−7.
【非特許文献41】 SREEJAYAN, N., and RAO, M.N.A. Nitric Oxide Scavenging by Curcuminoids. 1997. J Pharm Pharmacol. Vol. 49, pp. 105−7.
【非特許文献42】 SUNITHA, S., et al. Hepatoprotective Effect of Lupeol and Lupeol Linoleate on Tissue Antioxidant Defence System in Cadmium−induced Hepatotoxicity in Rats. 2001. Fitoterapia. Vol. 72, pp. 516−23.
【非特許文献43】 TAKEDA, S. and ABURADA, M.J. The Choleretic Mechanism of Coumarin Compounds and Phenolic Compounds. 1981. Pharmacobiodyn. Vol. 4, p. 724−34.
【非特許文献44】 TICLI, F., et al. Rosmarinic Acid, A New Snake Venom Phospholipase A2 Inhibitor from Cordia verbenacea (Boraginacea): Antiserum Action Potentiation and Molecular Interaction. 2005. Toxicon. Vol. 46, pp. 318−27.
【非特許文献45】 ZHU, M., et al. Triterpene Antioxidants from Ganoderma lucidum. 1999. Phytotherapy Research. Vol. 13, pp. 529−31.
【発明の概要】
【課題を解決するための手段】
本発明のハーブ組成物の抽出物は、それらのin vitroでの抗酸化作用を決定するために、初代ラット肝細胞培養を用いてテストした。一般的に、テストは、肝細胞の単離が実行されるまでthe Fe de Valencia Hospital Research Centerで飼育されていた、CRIFFA(Santa Perpetua de La Mogoda、バルセロナ)によって提供された雄ラット(Sprague Dawley)を用いて実行した。動物の取扱い及び屠殺は、国家規制、欧州連合の規定609/86、及びUS国立衛生研究所(NIH)によって刊行された実験動物の取扱い及び使用に従って実行した。
細胞生存率は、淡黄色物質であるジメチル−テトラゾリウム(MTT)の取り込み及び青色不溶性代謝産物であるホルマザンへの還元を測定することによって決定した。この細胞還元反応は、ミトコンドリア脱水素酵素活性を測定しており、この活性は細胞内小器官の完全性の程度に依存しており、従って培養中の生存細胞の数の明確な指標となる。この場合において、MTTは黄色を示すテトラゾリウム塩物質として使用され、ミトコンドリア脱水素酵素コハク酸活性によって青色不溶性代謝産物(ホルマザン)を産生し、これは、405〜630nmの範囲の吸光度を測定するELISAリーダーを用いて吸光度を測定することによって定量化され得る。
フリーラジカルの産生を定量化するために、96ウェルプレートに培養されたラット肝細胞の初代培養は、その無極性及びその非イオン性構造のおかげで細胞膜を通じてよく拡散し、酸素が存在すると蛍光を発する蛍光剤である5−クロロメチル−2’,7’−ジクロロヒドロフルオレセイン(DCFH−DA)と共に、以下の濃度:4、20、100及び500μg/mlでの本発明のハーブ組成物とインキュベートした(Lautraite S,Bigot−Lasserre D,Bars R and Carmichael N.Optimisation of cell−based assays for medium throughput screening of oxidative stress.Toxicol in vitro 17:207−220(2003)、これはこの参照によって本明細書に組込まれるものである)。インキュベーション期間が完了したら、細胞を本発明のハーブ組成物と共にt−ブチルヒドロペルオキシド(t−BOOH)に曝露し、その後すぐ蛍光発光を485nm(刺激)及び527nm(発光)で判読した(t0)。最終的に前記細胞は37℃でインキュベートし、蛍光は30分間隔で2時間判読した。ケルセチン(抗酸化作用を有することが知られているフラボノイド)で処理した細胞はテストのポジティブコントロールとして使用した(Boots A.W.,Bast A.and Haenen G.R.No role of DT−diaphorase(NqO1)in the protection against oxidized quercetin.FEBS Lett 579:677−682、これはこの参照によって本明細書に組込まれるものである)。定量化は、コントロール(ハーブ組成物の非存在下で酸化的刺激によって誘導された細胞)に対するフリーラジカルの%で示した。フリーラジカルを定量化するために、ハーブ組成物は0.5〜1%の範囲でエタノール−水溶液中に第一に溶解した。
脂質過酸化及びグルタチオン還元を測定するために、単離ラット肝細胞を80,000生細胞/cm2の密度で24ウェルプレートに培養した。1時間培養の安定化期間の後、細胞は4、20、100及び500μg/mlのハーブ組成物と共に24時間プレインキュベートした。プレインキュベーションが終了したら、細胞は、上述した濃度を用いて本発明の処方対象の有効成分と共に250μMのt−BOOHへ曝露した。24時間が経過したら、細胞を回収し、1200rpmで5分間遠心分離し;次にマロニルジアルデヒド(MDA)の産生を測定するために液体を回収した。単層を洗浄し、タンパク質及びグルタチオンレベル(GSH)を評価するために凍結させた。未処理細胞は、基礎酸化のコントロールとして使用し、t−ブチルヒドロペルオキシドで排他的に処理した細胞は、誘導酸化のコントロールとして使用した。
実施例4の抽出物及びコントロール物質(生理食塩水)は、以下の条件:
種:アルビノマウス(ハツカネズミ)
近交系:Balb/C/CNPB
動物の数:実験群当たり10匹の動物
性別:雄及び雌
体重:20〜25g
グループI(処理群):これらの動物には、2,000mg/kgの実施例4の抽出物の用量を投与
グループII(コントロール):これらの動物には、溶媒或いは生理食塩水(抽出物容積と同量)を投与
で、胃内カテーテルを用いて経口的に投与した。
実施例4の抽出物及びコントロール物質(生理食塩水)は、以下の条件:
種:アルビノラット(Rattus novergicus)
近交系:Holtzmann
動物の数:実験群当たり3匹の動物
性別:雄及び雌
体重:120〜160g
グループI(処理群):これらの動物には、2,000mg/kgの用量の実施例4の抽出物を投与
グループII(コントロール):これらの動物には、溶媒或いは生理食塩水(抽出物容積と同量)を投与
に従って、胃内カテーテルを用いて経口的に投与した。
Claims (16)
- 肝障害を治療するためのハーブ組成物であって、肝保護作用の性質を有するCordia lutea(ムユヨ)を有するものである、ハーブ組成物。
- 請求項1記載のハーブ組成物において、さらに、Annona muricata(トゲバンレイシ)、或いはCurcuma longa(ウコン)の少なくとも1つ、若しくはその両方を有するものである、ハーブ組成物。
- 請求項1記載のハーブ組成物において、前記Cordia lutea(ムユヨ)の花が使用されるものである、ハーブ組成物。
- 請求項3記載のハーブ組成物において、さらにAnnona muricata(トゲバンレイシ)の葉或いはCurcuma longa(ウコン)の根、若しくはその両方を有するものである、ハーブ組成物。
- 肝障害を治療するためのハーブ組成物であって、肝保護作用の性質を有するCordia lutea(ムユヨ)の抽出物を有するものである、ハーブ組成物。
- 請求項5記載のハーブ組成物において、さらに、Annona muricata(トゲバンレイシ)の抽出物、或いはCurcuma longa(ウコン)の抽出物、若しくはその両方を有するものである、ハーブ組成物。
- 請求項6記載の組成物において、前記Cordia lutea(ムユヨ)の抽出物はその花からによるものであり、前記Annona muricata(トゲバンレイシ)抽出物はその葉からによるものであり、及び前記Curcuma longa(ウコン)の抽出物はその根からによるものである、ハーブ組成物。
- 請求項7記載のハーブ組成物において、ムユヨの花、トゲバンレイシの葉、及びウコンの根の抽出物が全て、それぞれ1:1:1〜8:1:1の重量比で前記組成物に存在するものである、ハーブ組成物。
- 請求項7記載のハーブ組成物において、ムユヨの花、トゲバンレイシの葉、及びウコンの根の抽出物が全て、それぞれ1:0.025〜1:0.025〜1の重量比で前記組成物に存在するものである、ハーブ組成物。
- 請求項7記載のハーブ組成物において、ムユヨの花、トゲバンレイシの葉、及びウコンの根の抽出物は全て、それぞれ8:1:1の重量比で前記組成物に存在するものである、ハーブ組成物。
- 請求項5〜10いずれか一つに記載のハーブ組成物において、前記抽出物は含水アルコール抽出物である、ハーブ組成物。
- 患者における肝障害の治療或いは予防のための薬剤の調製における、治療上有効な量の請求項1〜11に記載されたハーブ組成物の使用。
- 請求項12記載の使用において、前記肝障害は、ウイルス感染によって引き起こされるものである、使用。
- 請求項13記載の使用において、前記ウイルス感染は、B型肝炎ウイルス、C型肝炎ウイルス、或いはその両者の組み合わせによって引き起こされるものである、使用。
- 請求項12記載の使用において、前記肝障害は、非ウイルス性肝炎である、使用。
- 請求項12記載の使用において、前記肝障害は、肝臓の線維化或いは肝硬変である、使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97725607P | 2007-10-03 | 2007-10-03 | |
US60/977,256 | 2007-10-03 | ||
PCT/CA2008/001764 WO2009043176A1 (en) | 2007-10-03 | 2008-10-03 | Herbal compositions and methods for treating hepatic disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010540572A JP2010540572A (ja) | 2010-12-24 |
JP2010540572A5 JP2010540572A5 (ja) | 2011-02-10 |
JP5486744B2 true JP5486744B2 (ja) | 2014-05-07 |
Family
ID=40525813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010527309A Expired - Fee Related JP5486744B2 (ja) | 2007-10-03 | 2008-10-03 | ムユヨの花、トゲバンレイシの葉、及びウコンの根の抽出物を含む、肝炎を治療するための組成物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US9775871B2 (ja) |
EP (1) | EP2205255B8 (ja) |
JP (1) | JP5486744B2 (ja) |
AR (1) | AR071731A1 (ja) |
BR (1) | BRPI0818178B1 (ja) |
CA (1) | CA2701190C (ja) |
ES (1) | ES2546402T3 (ja) |
HK (1) | HK1145995A1 (ja) |
MX (1) | MX2010003726A (ja) |
WO (1) | WO2009043176A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120213870A1 (en) * | 2011-02-17 | 2012-08-23 | Maher El-Aaser | Composition and method for treating liver disease |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
CN104383541A (zh) | 2011-10-21 | 2015-03-04 | 艾伯维公司 | 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法 |
DK2583680T1 (da) | 2011-10-21 | 2015-01-19 | Abbvie Inc | Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US20140056828A1 (en) * | 2012-08-21 | 2014-02-27 | Indiran Pather | Novel formulations and uses for curcuma extracts |
KR20200128438A (ko) | 2012-11-26 | 2020-11-12 | 액세스 비지니스 그룹 인터내셔날 엘엘씨 | 항산화 식이 보충제 및 관련 방법 |
JP6457749B2 (ja) * | 2013-12-27 | 2019-01-23 | ハウスウェルネスフーズ株式会社 | Vcam−1発現抑制剤 |
CN104208581A (zh) * | 2014-08-27 | 2014-12-17 | 青岛恒波仪器有限公司 | 一种预防酒精肝的五味子保健口服液及其制备方法 |
CA3022119A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
KR101872622B1 (ko) * | 2016-12-20 | 2018-06-29 | 세종대학교산학협력단 | 니코틴 독성 해독용 그라비올라 추출물 제조방법 및 이 추출물을 함유하는 해독용 음료 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4137540A1 (de) * | 1991-11-14 | 1993-05-19 | Steigerwald Arzneimittelwerk | Verwendung von praeparaten der curcuma-pflanzen |
AUPN411195A0 (en) * | 1995-07-10 | 1995-08-03 | Cathay Herbal Laboratories Pty Ltd | Medicinal composition |
US5861415A (en) * | 1996-07-12 | 1999-01-19 | Sami Chemicals & Extracts, Ltd. | Bioprotectant composition, method of use and extraction process of curcuminoids |
KR100239879B1 (ko) | 1997-11-05 | 2000-02-01 | 김상조 | 간암 예방 및 치료용 생약제 |
ES2154610B1 (es) * | 1999-09-23 | 2001-11-16 | Asac Compania De Biotecnologia | Nuevas actividades farmacologicas de los extractos de curcuma longa. |
AU2002348802A1 (en) * | 2001-12-14 | 2003-06-30 | Council Of Scientific And Industrial Research | Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders |
US20040101584A1 (en) | 2002-11-22 | 2004-05-27 | Mclaughlin Jerry Loren | Control of cancer with annonaceous extracts |
US7320797B2 (en) * | 2003-08-29 | 2008-01-22 | Bioderm Research | Antiaging cosmetic delivery systems |
US20050084547A1 (en) * | 2003-09-12 | 2005-04-21 | Phytomyco Research Corporation | Natural product based apoptosis inducers |
CN1269521C (zh) | 2004-07-01 | 2006-08-16 | 邢乐道 | 一种治疗癌症的复方药物及其制备方法 |
US7973992B2 (en) | 2008-04-14 | 2011-07-05 | Dai Nippon Printing Co., Ltd. | Imaging device for avoidance of an obstacle or an optical phenomenon which distorts quality of image |
-
2008
- 2008-10-03 WO PCT/CA2008/001764 patent/WO2009043176A1/en active Application Filing
- 2008-10-03 ES ES08800424.7T patent/ES2546402T3/es active Active
- 2008-10-03 CA CA2701190A patent/CA2701190C/en active Active
- 2008-10-03 BR BRPI0818178-0A patent/BRPI0818178B1/pt active IP Right Grant
- 2008-10-03 US US12/681,066 patent/US9775871B2/en active Active
- 2008-10-03 MX MX2010003726A patent/MX2010003726A/es active IP Right Grant
- 2008-10-03 JP JP2010527309A patent/JP5486744B2/ja not_active Expired - Fee Related
- 2008-10-03 EP EP08800424.7A patent/EP2205255B8/en active Active
- 2008-10-17 AR ARP080104538A patent/AR071731A1/es not_active Application Discontinuation
-
2011
- 2011-01-13 HK HK11100309.3A patent/HK1145995A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2205255B8 (en) | 2015-09-30 |
JP2010540572A (ja) | 2010-12-24 |
BRPI0818178B1 (pt) | 2021-11-23 |
CA2701190C (en) | 2017-12-05 |
EP2205255A4 (en) | 2012-02-29 |
WO2009043176A9 (en) | 2009-07-02 |
AR071731A1 (es) | 2010-07-14 |
EP2205255A1 (en) | 2010-07-14 |
CA2701190A1 (en) | 2009-04-09 |
US9775871B2 (en) | 2017-10-03 |
HK1145995A1 (en) | 2011-05-13 |
ES2546402T3 (es) | 2015-09-23 |
BRPI0818178A2 (pt) | 2020-06-23 |
WO2009043176A1 (en) | 2009-04-09 |
MX2010003726A (es) | 2010-09-14 |
US20100260874A1 (en) | 2010-10-14 |
EP2205255B1 (en) | 2015-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5486744B2 (ja) | ムユヨの花、トゲバンレイシの葉、及びウコンの根の抽出物を含む、肝炎を治療するための組成物 | |
Kumar et al. | Phytochemical investication and heptoprotective evalution acacia rubica extract isonized and paracetamol indused animal toxicity | |
Rong et al. | A 35-day gavage safety assessment of ginger in rats | |
TWI300352B (en) | Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract | |
RU2700793C2 (ru) | Фармацевтическая композиция, содержащая силибин, витамин е и l-карнитин | |
TWI444194B (zh) | 抗癌萃取物及化合物 | |
Kuraoka-Oliveira et al. | Anti-inflammatory and anti-arthritic activity in extract from the leaves of Eriobotrya japonica | |
Karbab et al. | Anti-inflammatory, analgesic activity, and toxicity of Pituranthos scoparius stem extract: An ethnopharmacological study in rat and mouse models | |
Swamy et al. | Phytochemical analysis of Vernonia adoensis leaves and roots used as a traditional medicinal plant in Kenya | |
Kosasih et al. | Hepatoprotective effect of citrus sinensis peel extract against isoniazid and rifampicin-induced liver injury in wistar rats | |
JP2011503237A (ja) | Scutellariabarbatad.donの精製抽出物を作製するためのプロセス | |
Wattanapitayakul et al. | Vasorelaxation and antispasmodic effects of Kaempferia parviflora ethanolic extract in isolated rat organ studies | |
JP7317309B2 (ja) | オートファジー性細胞死誘導剤 | |
JP2017533264A (ja) | 抗炎症性、増殖性、保護性及び粘膜付着性の、可溶性且つ安定な医薬組成物、粘膜部位の状態を治療するためのその使用及び取得方法、並びに医薬組成物の調製のための基本医薬組成物及びその取得方法 | |
KR100414187B1 (ko) | 흰점박이꽃무지 추출물 및 이의 용도 | |
Campuzano-Bublitz et al. | Acute and chronic anti-hyperglycemic effect of Prosopis ruscifolia extract in normoglycemic and alloxan-induced hyperglycemic rats | |
JPH04300836A (ja) | 肝機能障害予防剤及び肝機能障害予防作用を有する機能性食品 | |
KR100411370B1 (ko) | 면역증강 및 생리활성 효과를 갖는 씀바귀 추출물 | |
KR20110061108A (ko) | 흰민들레 추출물을 유효성분으로 함유하는 간암 예방 또는 치료용 조성물 | |
KR100529991B1 (ko) | 간염 치료제 및 예방제 또는 간보호제로 유용한 섬오갈피추출물 | |
JP2002510640A (ja) | エイズの予防及び治療用薬草組成物 | |
Obiekwe et al. | Prophylactic activities of Olax viridis in the liver of rats challenged with carbon tetrachloride | |
Juwita et al. | Hepatoprotective effect of Indonesian propolis from in carbon tetrachloride (CCl) induced liver injury in mice | |
Gangwar et al. | PHARMACOLOGICAL AND PHYTOCHEMICAL SREENING OF IN-VITRO HEPATOPROTECTIVE ACTIVITY OF AAK (CALOTROPIS PROCERA) | |
Nguyen et al. | Anti-atherosclerotic effects of Camellia chrysantha and Gynostemma pentaphyllum extracts mixture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101115 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101115 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130313 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130321 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130416 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130423 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130520 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130625 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130925 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131002 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131023 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131030 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131123 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140128 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140222 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5486744 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |